Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591917 | 1.00 | MAP4K4 (0.49) | MAP4K4HDAC1SUV39H2GPR119TRPV1 | |
| SCHEMBL1591916 | 1.00 | MAP4K4 (0.49) | MAP4K4HDAC1SUV39H2GPR119TRPV1 | |
| SCHEMBL1579305 | 0.86 | CHRM4 (0.42) | SUV39H2TRPV1PIK3CDCHRM4PANK3 | |
| SCHEMBL1579583 | 0.86 | CHRM4 (0.42) | SUV39H2TRPV1PIK3CDCHRM4PANK3 | |
| SCHEMBL1579308 | 0.86 | CHRM4 (0.42) | SUV39H2TRPV1PIK3CDCHRM4PANK3 | |
| SCHEMBL31275247 | 0.85 | MAP4K4 (0.52) | MAP4K4HDAC1SUV39H2GPR119TRPV1 | |
| SCHEMBL1581021 | 0.83 | CKS1B (0.46) | MAP4K4SUV39H2GPR119NR1H2 | |
| SCHEMBL21551664 | 0.82 | GPR119 (0.49) | MAP4K4HDAC1SUV39H2GPR119CHRM4 | |
| SCHEMBL28551924 | 0.82 | GPR119 (0.49) | MAP4K4HDAC1SUV39H2GPR119CHRM4 | |
| SCHEMBL14819003 | 0.82 | MAP4K4 (0.50) | MAP4K4HDAC1SUV39H2GPR119TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150230-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | MAP4K4 4449/4885HDAC1 2549/4885SUV39H2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.